It’s always a good idea to pay attention to insider buying. After all, it’s the insiders who know their company the best. And ...

Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing round. The round was led by ...

GRAIL, Inc. was spun off from Illumina in 2024 and offers a promising multi-cancer early detection test called Galleri. Click ...

Illumina Inc. (NASDAQ: ILMN), aligned with its commitments to advance the power of genomics, today published its annual ...

Genomics company Illumina (NASDAQ:ILMN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell ...

Illumina Inc. ILMN recently introduced PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. PromoterAI turns ...

Illumina, Inc. (NASDAQ:ILMN) has introduced PromoterAI, a breakthrough AI tool designed to detect disease-causing mutations in the noncoding promoter regions of the genome, areas often overlooked in ...

Illumina, Inc. (NASDAQ:ILMN) has introduced PromoterAI, a breakthrough AI tool designed to detect disease-causing mutations in the noncoding promoter regions of the genome, areas often overlooked ...

Analysts' ratings for Illumina (NASDAQ:ILMN) over the last quarter vary from bullish to bearish, as provided by 15 analysts. Summarizing their recent assessments, the table below illustrates the ...

Read Our Latest Stock Report on Illumina Illumina Stock Up 7.7% Shares of NASDAQ:ILMN opened at $81.57 on Monday. The company has a market capitalization of $12.91 billion, a PE ratio of -10.62, a ...

Genomics company Illumina (NASDAQ:ILMN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 1.4% year on year to $1.04 billion. Its non-GAAP profit of $0.97 per ...